The reader should take in consideration that while CD38 has been extensively studied from the biological standpoint over the years and is now widely adopted as a marker in the clinical practice, the enzymes of the ATP-dismantling cascade gained visibility in the field of hematological malignancies only recently. The gene discussed is CD38; the disease is hematologic disorder.